Drug
GLPG2222 clinical trials
Also written ABBV-2222 and Galicaftor.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Navocaftor (4) · ABBV-576 (1) · ABBV-119 (1)
Studies
Open first, then newest update. How each study uses GLPG2222 is read from its arms, and is right about nine times in ten.
Testing it · 7
- Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic FibrosisTerminatedPhase 2AbbVieNCT04853368Written as Galicaftor
- A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222CompletedPhase 2AbbVieNCT03969888Written as ABBV-2222
- A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic FibrosisCompletedPhase 1AbbVieNCT05530278Written as Galicaftor
- A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and NavocaftorCompletedPhase 1AbbVieNCT05538585Written as Galicaftor
- A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic FibrosisCompletedPhase 2Galapagos NVNCT03119649Written as GLPG2222 50 mg
- A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic FibrosisCompletedPhase 2Galapagos NVNCT03045523Written as GLPG2222 150 mg q.d.
- First-in-Human Single and Multiple Dose of GLPG2222CompletedPhase 1Galapagos NVNCT02662452Written as GLPG2222 single dose